Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 386
Out of 5,182 analysts
96
Total ratings
55.07%
Success rate
18.14%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $140 → $200 | $135.30 | +47.82% | 1 | Apr 14, 2026 | |
| UPB Upstream Bio | Downgrades: In-Line | $40 → $15 | $9.31 | +61.12% | 2 | Mar 27, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $31.58 | +42.50% | 3 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $100 → $125 | $73.28 | +70.58% | 4 | Feb 25, 2026 | |
| ACLX Arcellx | Downgrades: In-Line | $115 | $115.03 | -0.03% | 2 | Feb 24, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $10.37 | +73.58% | 2 | Feb 24, 2026 | |
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $50.73 | -31.01% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $751.57 | +16.42% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $23.56 | +69.78% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $18.19 | +202.36% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $27.11 | +29.10% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $10.24 | +144.14% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $65.32 | +22.47% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $22.08 | +53.99% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $55.24 | -0.43% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $127.68 | +44.89% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $105.46 | +18.53% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $53.18 | +97.44% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $24.10 | +265.15% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $184.38 | +49.69% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.29 | +963.83% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $344.55 | -32.67% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $94.65 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $130.40 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $33.31 | -36.96% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $7.54 | +205.04% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.68 | +495.24% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $16.77 | - | 5 | Feb 14, 2018 |
Revolution Medicines
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $200
Current: $135.30
Upside: +47.82%
Upstream Bio
Mar 27, 2026
Downgrades: In-Line
Price Target: $40 → $15
Current: $9.31
Upside: +61.12%
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $31.58
Upside: +42.50%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $100 → $125
Current: $73.28
Upside: +70.58%
Arcellx
Feb 24, 2026
Downgrades: In-Line
Price Target: $115
Current: $115.03
Upside: -0.03%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $10.37
Upside: +73.58%
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $50.73
Upside: -31.01%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $751.57
Upside: +16.42%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $23.56
Upside: +69.78%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $18.19
Upside: +202.36%
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $27.11
Upside: +29.10%
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $10.24
Upside: +144.14%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $65.32
Upside: +22.47%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $22.08
Upside: +53.99%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $55.24
Upside: -0.43%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $127.68
Upside: +44.89%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $105.46
Upside: +18.53%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $53.18
Upside: +97.44%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $24.10
Upside: +265.15%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $184.38
Upside: +49.69%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.29
Upside: +963.83%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $344.55
Upside: -32.67%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $94.65
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $130.40
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $33.31
Upside: -36.96%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $7.54
Upside: +205.04%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.68
Upside: +495.24%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $16.77
Upside: -